MEP36508A - Triazolopyrazine derivatives useful as anti-cancer agents - Google Patents

Triazolopyrazine derivatives useful as anti-cancer agents

Info

Publication number
MEP36508A
MEP36508A MEP-365/08A MEP36508A MEP36508A ME P36508 A MEP36508 A ME P36508A ME P36508 A MEP36508 A ME P36508A ME P36508 A MEP36508 A ME P36508A
Authority
ME
Montenegro
Prior art keywords
cancer agents
derivatives useful
triazolopyrazine derivatives
compounds
formula
Prior art date
Application number
MEP-365/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Hengmiao Cheng
Jingrong Jean Cui
Jacqui Elizabeth Hoffman
Lei Jia
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MEP36508A publication Critical patent/MEP36508A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-365/08A 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents MEP36508A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79996606P 2006-05-11 2006-05-11
US89323107P 2007-03-06 2007-03-06
PCT/IB2007/001142 WO2007132308A1 (en) 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents

Publications (1)

Publication Number Publication Date
MEP36508A true MEP36508A (en) 2011-02-10

Family

ID=38441445

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-365/08A MEP36508A (en) 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents

Country Status (32)

Country Link
US (2) US7732604B2 (es)
EP (1) EP2018383B1 (es)
JP (1) JP4377962B2 (es)
KR (1) KR101099161B1 (es)
CN (1) CN101443331A (es)
AP (1) AP2008004674A0 (es)
AR (1) AR060994A1 (es)
AT (1) ATE532785T1 (es)
AU (1) AU2007251283A1 (es)
BR (1) BRPI0711809A2 (es)
CA (1) CA2651363C (es)
CR (1) CR10383A (es)
EA (1) EA016204B1 (es)
EC (1) ECSP088871A (es)
ES (1) ES2376913T3 (es)
GE (1) GEP20115174B (es)
GT (1) GT200700039A (es)
HN (1) HN2007015177A (es)
IL (1) IL194813A0 (es)
MA (1) MA30411B1 (es)
ME (1) MEP36508A (es)
MX (1) MX2008014399A (es)
NL (1) NL2000613C2 (es)
NO (1) NO20085060L (es)
NZ (1) NZ572361A (es)
PE (1) PE20080067A1 (es)
RS (1) RS20080533A (es)
TN (1) TNSN08445A1 (es)
TW (1) TWI346115B (es)
UY (1) UY30334A1 (es)
WO (1) WO2007132308A1 (es)
ZA (1) ZA200809020B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198448B2 (en) * 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
MX2010009414A (es) * 2008-02-28 2010-09-24 Novartis Ag Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met.
JP2011515343A (ja) * 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
JPWO2009157196A1 (ja) * 2008-06-25 2011-12-08 武田薬品工業株式会社 アミド化合物
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
JP2012509342A (ja) * 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
AU2009325072A1 (en) * 2008-12-12 2011-06-30 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
MY160526A (en) 2008-12-22 2017-03-15 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
ES2433090T3 (es) * 2009-05-28 2013-12-09 Vertex Pharmaceuticals Incorporated Inhibidores a base de aminopirazol triazolotiadiazol de la proteína cinasa c-met
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) * 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
DE102009056886A1 (de) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
KR101905350B1 (ko) * 2009-12-31 2018-11-30 허치슨 메디파르마 리미티드 특정 트리아졸로피리딘 및 트리아졸로피라진, 이들의 조성물 및 이들의 사용 방법
TWI423974B (zh) * 2010-02-11 2014-01-21 Hutchison Medipharma Ltd 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
JP2013526570A (ja) 2010-05-14 2013-06-24 オーエスアイ・ファーマシューティカルズ，エルエルシー 縮合二環式キナーゼ阻害剤
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN103204844A (zh) 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
MY169268A (en) 2012-03-30 2019-03-20 Rhizen Pharmaceuticals S A Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
US20150051210A1 (en) 2012-04-03 2015-02-19 Novartis Ag Tyrosine Kinase Inhibitor Combinations and their Use
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
CN105968115B (zh) * 2013-04-17 2018-11-09 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
DK3053923T3 (en) * 2013-09-30 2018-07-23 Korea Res Inst Chemical Tech TRIAZOLOPYRAZINE DERIVATIVES AS TYROSIN KINASE INHIBITORS
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP2018123059A (ja) * 2015-06-10 2018-08-09 石原産業株式会社 １−シクロプロピルエチルアミン又はその塩の製造方法
MX2018000880A (es) * 2015-07-20 2018-08-24 Genzyme Corp Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
WO2017049711A1 (zh) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用
WO2017114452A1 (zh) * 2015-12-31 2017-07-06 上海医药集团股份有限公司 喹啉类化合物的盐，其晶型、制备方法、组合物与应用
KR20230042756A (ko) 2016-03-15 2023-03-29 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
ES2975263T3 (es) * 2016-06-20 2024-07-04 Novartis Ag Formas cristalinas de un compuesto triazolopirimidínico
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
CN108276418A (zh) * 2018-03-20 2018-07-13 北京凯恩梅格医药科技有限公司 化合物、含有该化合物的药用组合物及其用途
CN113412112B (zh) 2018-12-14 2024-06-11 贝达医药公司 作为c-MET抑制剂的有机磷取代化合物及其治疗用途
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69334351D1 (de) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetisches Bindeprotein für Tumormarker
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
DE69718472T2 (de) 1996-07-13 2003-11-06 Glaxo Group Ltd., Greenford Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CZ2002936A3 (cs) * 1999-09-17 2002-10-16 Abbott Gmbh & Co. Kg Pyrazolopyrimidiny jako terapeutické prostředky
CA2530589A1 (en) * 2003-07-02 2005-01-20 Sugen Inc. Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
CA2537916A1 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US9665874B2 (en) 2012-03-13 2017-05-30 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
EP2018383A1 (en) 2009-01-28
NO20085060L (no) 2008-12-03
KR101099161B1 (ko) 2011-12-27
US7732604B2 (en) 2010-06-08
NZ572361A (en) 2012-02-24
NL2000613C2 (nl) 2007-11-20
CA2651363A1 (en) 2007-11-22
AU2007251283A1 (en) 2007-11-22
US20070265272A1 (en) 2007-11-15
GEP20115174B (en) 2011-03-10
BRPI0711809A2 (pt) 2011-12-06
ECSP088871A (es) 2008-12-30
IL194813A0 (en) 2009-08-03
AP2008004674A0 (en) 2008-12-31
CA2651363C (en) 2011-07-12
UY30334A1 (es) 2008-01-02
ES2376913T3 (es) 2012-03-20
ZA200809020B (en) 2009-12-30
JP4377962B2 (ja) 2009-12-02
KR20090006187A (ko) 2009-01-14
EP2018383B1 (en) 2011-11-09
RS20080533A (en) 2009-09-08
TWI346115B (en) 2011-08-01
TW200804384A (en) 2008-01-16
GT200700039A (es) 2008-06-02
JP2009536636A (ja) 2009-10-15
PE20080067A1 (es) 2008-03-10
EA016204B1 (ru) 2012-03-30
MA30411B1 (fr) 2009-05-04
CR10383A (es) 2008-11-11
CN101443331A (zh) 2009-05-27
AR060994A1 (es) 2008-07-30
TNSN08445A1 (fr) 2010-04-14
EA200870423A1 (ru) 2009-04-28
MX2008014399A (es) 2008-11-27
HN2007015177A (es) 2010-06-09
US20100105656A1 (en) 2010-04-29
ATE532785T1 (de) 2011-11-15
WO2007132308A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
MEP36508A (en) Triazolopyrazine derivatives useful as anti-cancer agents
HRP20050933A2 (en) Organic compounds
MEP43308A (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
HRP20070505B1 (hr) Spiro-oksindol spojevi i njihove upotrebe kao terapijska sredstva
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
CY1112401T1 (el) Παραγωγα πυριδαζινης
EA200870282A1 (ru) Производные амина
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
UY30407A1 (es) Derivados de [2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-8-il]-fenil sulfonatos sustituidos, composiciones farmacéuticas y aplicaciones.
ME00590A (en) N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
TW200730511A (en) Chroman compounds
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique